RT Journal Article
SR Electronic
T1 Multi-nutrients as Adjunctive Treatment for Bipolar Disorder: A randomized-controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.06.23.23291534
DO 10.1101/2023.06.23.23291534
A1 Mehl-Madrona, Lewis
A1 McFarlane, Patrick
YR 2023
UL http://medrxiv.org/content/early/2023/06/29/2023.06.23.23291534.abstract
AB Introduction An open-label trial suggested that a comprehensive micronutrient supplement, Empower Plus Advanced, in combination with Fish Oil, could reduce symptoms in adults with bipolar disorder. A double-blind, randomized, controlled feasibility trial explored the parameters necessary for a large-scale trial.Methods Participants (N=69) from a family medicine training clinic with diagnoses of bipolar disorder in the electronic health record were randomized in a 3:2 ratio to Multi-nutrients or Placebo. Diagnoses were confirmed via psychiatric interview or chart review (for obvious cases). The primary outcome measure was change on a composite z-score combining changes on the clinical global impressions scale (CGI), changes on the UKU Side Effects Scale, and changes in medication doses. The GLM repeated measures procedure of SPSS compared continuous outcome measures. Chi-square testing compared responders to non-responders.Results Data were analyzed for 50 participants. The mean difference of the composite z-score for the primary outcome variables was statistically significant (p = 0.019) and for the composite z-score of all variables (primary and secondary) combined (p = 0.047). In non-parametric chisquare analysis, significantly more in the Nutrient group improved on the CGI (rated 1 or 2) (p = 0.04; OR = 4.0; 52% responders vs. 22% in the Placebo Group). All secondary outcome measures showed nonsignificant trends in the expected direction. Patients in both groups made significant improvement in all measures. The only adverse events occurring more among the Multi-nutrient group were nausea and loose stools, not statistically significant.Conclusions Multi-nutrients show promise for adjunctive treatment of bipolar disorder. We observed substantial benefits for all patients of closer surveillance, medication adjustment (mostly reduction), and increased human contact. Future studies would benefit from use of a longer lead-in period during which medications can be adjusted and participants can decide if they are willing to take Multi-nutrients for an extended time. Our data suggest that primary care patients with bipolar disorder would fare better on lower medications doses and more frequent visits. Further clinical trials are warranted.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03541031Funding StatementThe study was funded for the Institute for Excellence in Mental HealthAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northern Light Eastern Maine Medical Center IRB approved and monitored this study.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData contains protected health information and according to our IRB cannot be shared.